ArticleScientific reports2025
Platelet like cells differentiated from human adipose derived mesenchymal stem cells promote healing of tendinopathy in rats.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Tendon and ligament disorders, such as tendinopathy, cause pain and limit levels of activities of daily living. Thus, devising methods to heal them is crucial. Although treatment with autologous platelet rich plasma (PRP) is reportedly useful against tendon injury, PRP requires blood sampling and its quality varies. Here we show that platelet-like cells (ASCL-PLCs) derived from a heterologous human adipose-derived mesenchymal stem cell line (ASCL) promote significant tendon repair in a collagenase-induced injury model in rat Achilles tendons. Single administration of human ASCL-PLCs to rat Achilles tendon after 2 weeks of collagenase treatment significantly increased tendon strength and improved semi-quantitative histological evaluation scores in 4 weeks relative to PBS-treated controls. Moreover, xeno-graft reactions were not evident in ASCL-PLC-administered rats. In vitro, ASCL-PLC treatment significantly upregulated Col1a1, Lox and Mkx gene expression in NIH3T3 fibroblasts and activated ERK signaling. Overall, ASCL-PLCs could serve as a useful tool to repair injured tendons and treat tendinopathy. This approach eliminates the need for blood sampling, ensures consistent quality, supports xeno-transplantation, and increases injured tendon strength.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.